Jan 28 (Reuters) - Eikon ‍Therapeutics is targeting a valuation of up to $908.2 million in its U.S. initial public offering, ...

By Arasu Kannagi Basil Jan 28 (Reuters) - Eikon ‍Therapeutics, headed by Merck veteran Roger Perlmutter, is targeting a valuation of up to $908.2 million in its initial public offering in the United ...

The oncology biotech plans to offer 17,648,000 shares at $17 a pop, according to a Jan. 28 filing with the Securities and Exchange Commission. The maximum price outlined by Eikon is $18 per share, ...

Merck (NYSE:MRK) has ended acquisition talks with Revolution Medicines after the parties could not agree on valuation. The ...

The South San Francisco start-up is offering 17.6 million shares at a price range of $16 to $18, which would give the company ...

Merck (MRK) veteran Roger Perlmutter led Eikon Therapeutics (EIKN) files for its U.S. IPO seeking a valuation of up to $908M.

Eikon Therapeutics Inc. filed for an initial public offering to help fund its advanced pipeline of cancer drugs.

Two more biopharma companies—the hair-growth specialist Veradermics and cancer-focused Eikon Therapeutics—have announced ...

Run by Roger Perlmutter and backed by more than $1 billion in private funding, Eikon will use the IPO proceeds to advance a ...

Eikon Therapeutics, the drug discovery startup with a former Merck & Co. research chief at the helm, has appointed a pantheon of biotech veterans on its quest to take its live-cell imaging platform to ...